CI$274.74
Chart
Performance
Key Stats
AI CI Summary
Powered by LiveAIAI Scoreboard
Powered by LiveAIOverall Analysis
BuyThe Cigna Group presents a mixed but generally positive investment profile. Strong fundamental performance, particularly in profitability and cash flow, is offset by a slight uptick in debt and a current overvaluation based on trailing earnings. Thematic exposure is moderate, with a focus on healthcare services and managed care.
Thematic
The Cigna Group operates within the healthcare and insurance sectors, which benefit from demographic trends such as an aging population and increased demand for healthcare services. However, it faces regulatory headwinds and evolving market dynamics.
Fundamental
The Cigna Group demonstrates strong profitability and a solid balance sheet with consistent revenue generation. While debt has increased slightly, it remains manageable given its free cash flow. Valuation metrics indicate a potential for overvaluation based on trailing P/E, but forward-looking estimates may be more favorable.
Technical
The Cigna Group's stock is currently trading below key moving averages and exhibits weak momentum across multiple timeframes, suggesting a bearish short-term outlook. However, it is approaching significant support levels which could offer a potential rebound.
| Factor | Score |
|---|---|
| Healthcare Services Demand | 85 |
| Managed Care & Pharmacy Benefits | 80 |
| Regulatory Environment | 50 |
| Innovation in Healthcare | 60 |
| Economic Sensitivity | 55 |
| Factor | Score |
|---|---|
| Valuation | 55 |
| Profitability | 70 |
| Growth | 85 |
| Balance Sheet Health | 75 |
| Cash Flow | 88 |
| Dividend Yield | 70 |
| Factor | Score |
|---|---|
| Trend Analysis | 30 |
| Momentum | 40 |
| Volume Analysis | 70 |
| Support & Resistance | 60 |
| Short-term Oscillators | 70 |
AI Investing Checklist
Powered by LiveAIBullish Points (7)
Positive EPS Surprises
The company has exceeded earnings per share (EPS) estimates in 8 out of the last 12 reported quarters, indicating consistent operational performance and effective management.
Undervalued P/E Ratio
The trailing Price-to-Earnings (P/E) ratio of 16.39 is lower than the industry average of 20.0, suggesting the stock may be undervalued relative to its earnings.
Bearish Points (7)
Recent EPS Miss
The company missed its EPS estimate for Q1 2025 by 15.14%, indicating potential challenges in meeting analyst expectations for future quarters.
High P/S Ratio
The trailing Price-to-Sales (P/S) ratio of 0.4 is relatively low, but the quarterly P/S ratio for Q1 2025 (1.3) and Q4 2024 (1.1) suggests increasing valuation concerns relative to revenue.
Calendar
June 2025
18
Next Dividend Date
July 2025
31
Next Earnings Date
H: $7.39
A: $7.15
L: $7.08
H: 65.01B
A: 62.61B
L: 60.11B
September 2025
4
Ex-Dividend Date
Profile
The Cigna Group, together with its subsidiaries, provides insurance and related products and services in the United States. Its Evernorth Health Services segment provides a range of coordinated and point solution health services, including pharmacy benefits, home delivery pharmacy, specialty pharmacy, distribution, and care delivery and management solutions to health plans, employers, government organizations, and health care providers. The company's Cigna Healthcare segment offers medical, pharmacy, behavioral health, dental, and other products and services for insured and self-insured customers; Medicare Advantage, Medicare Supplement, and Medicare Part D plans for seniors, as well as individual health insurance plans; and health care coverage in its international markets, as well as health care benefits for mobile individuals and employees of multinational organizations. In addition, it offers permanent insurance contracts sold to corporations to provide coverage on the lives of certain employees for financing employer-paid future benefit obligations and stop loss insurance. The company distributes its products and services through insurance brokers and consultants; directly to employers, unions and other groups, or individuals; and private and public exchanges. The company was formerly known as Cigna Corporation and changed its name to The Cigna Group in February 2023. The company was founded in 1792 and is headquartered in Bloomfield, Connecticut.
Seasonals
Price Target
374.28 USD
The 39 analysts offering 1 year price forecasts for CI have a max estimate of 407.00 and a min estimate of 330.60.
Debt Level and Coverage
Financial Position Analysis
Ownership
Capital Structure
Valuation - Summary
Valuation - Ratios
Revenue to Profit Conversion
Balance Sheet
Income Statement
Cash Flow
Related Companies
Powered by LiveAIWeight: 95
Cigna's primary and largest competitor in both health insurance and pharmacy benefit management (OptumRx), driving market share and competitive dynamics.
Weight: 92
A diversified healthcare company owning Aetna (health insurance) and Caremark (pharmacy benefit manager), making it a direct competitor across Cigna's core segments.
Weight: 90
A leading competitor in the U.S. health insurance market, particularly strong in state-based plans and Blue Cross Blue Shield affiliations.
Weight: 88
Major competitor with a strong focus on Medicare Advantage plans, a key growth area for insurers, and a significant player in integrated care delivery.